Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

Myrthe P. P. van Herk-Sukel*, Lonneke V. van de Poll-Franse, Adri C. Voogd, Grard A. P. Nieuwenhuijzen, Jan-Willem Coebergh, Ron M. C. Herings

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

79 Citations (Web of Science)
Original languageEnglish
Pages (from-to)843-851
JournalBreast Cancer Research and Treatment
Issue number3
Publication statusPublished - Aug 2010


  • Adjuvant endocrine therapy
  • Aromatase inhibitors
  • Discontinuation
  • Early stage breast cancer
  • Recurrence
  • Switching
  • Tamoxifen

Cite this